/Boston%20Scientific%20Corp_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $154.3 billion, Boston Scientific Corporation (BSX) is a global developer, manufacturer, and marketer of medical devices used across a wide range of interventional medical specialties. With a diversified portfolio and a mix of organic growth and strategic acquisitions, the company operates through key segments including Cardiovascular, Rhythm and Neuro, and MedSurg.
The Marlborough, Massachusetts-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Wednesday, Jul. 23. Ahead of the event, analysts expect BSX to report an adjusted EPS of $0.72, up 16.1% from $0.62 in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports.
For fiscal 2025, analysts expect the medical device manufacturer to report adjusted EPS of $2.91, representing a 15.9% increase from $2.51 in fiscal 2024.
Shares of BSX have surged 37.1% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 13.4% rise and the Health Care Select Sector SPDR Fund's (XLV) 5.4% decline over the same period.
Shares of Boston Scientific climbed 4.1% on Apr. 23 after the company reported better-than-expected Q1 2025 adjusted EPS of $0.75 and revenue of $4.7 billion. The company raised its 2025 adjusted EPS guidance to a range of $2.87 - $2.94, signaling confidence in sustained demand for its medical devices. Additionally, Boston Scientific reassured investors that it expects to absorb a potential $200 million tariff impact through higher sales and discretionary spending cuts, bolstered by expanded U.S. manufacturing capacity.
Analysts' consensus rating on Boston Scientific stock is bullish, with a "Strong Buy" rating overall. Among 30 analysts covering the stock, 27 recommend a "Strong Buy,” two have a "Moderate Buy" rating, and one gives a "Hold" rating. This configuration is more bullish than three months ago, with 25 analysts suggesting a "Strong Buy."
As of writing, BSX is trading below the average analyst price target of $120.50.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
